On December 12, 2023, Coya Therapeutics, Inc. closed the transaction. The securities are issued pursuant to exemption provided under Regulation D. The transaction included participation from 122 investors. The Company paid BTIG and Newbridge a fee based on gross proceeds from the sale of securities placed by each placement agent respectively and issued to Newbridge a warrant exercisable for 196,168 shares of Common Stock.